Clinical trials recruiting for Advanced Cancer

Phase breakdown

Drugs and treatments being studied

Where trials are recruiting (top US states)

Top cities

Self-screener

Recruiting trials

• A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma
  NCT03829254 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
  NCT06228326 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 14 locations
• A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
  NCT04657068 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 164 locations
• A Study of MGC026 in Participants With Advanced Solid Tumors
  NCT06242470 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 36 locations
• A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
  NCT05859074 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
  NCT06362369 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• A Study of PHN-012 in Patients With Advanced Solid Tumors
  NCT07127874 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 78 locations
• A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
  NCT06210776 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 54 locations
• A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
  NCT06440005 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
  NCT03175224 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 35 locations
• Analysis of PD-L1, TMB, MSI and ctDNA Dynamics to Predict and Monitor Response to Immunotherapy in Metastatic Cancer.
  NCT06227728 · Phase: Not specified · Ages: 18 Years to 80 Years · Sex: All (male and female) · 4 locations
• Descriptive Observational Study on the Characteristics of Advanced and Metastatic Melanoma in Spain
  NCT03605771 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 39 locations
• High Definition Medicine for Solid Tumors Oncology
  NCT06590506 · Phase: Not specified · Ages: 18 Years and older · Sex: Female · 18 locations
• MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
  NCT05076760 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer
  NCT04146298 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC
  NCT06405490 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Non Inferiority Study of Preoperative Chemotherapy Without Pelvic Irradiation for Rectal Cancer
  NCT03875781 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
  NCT05735080 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 18 locations
• Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy
  NCT06200155 · Phase: Phase 2 · Ages: 25 Years and older · Sex: All (male and female) · 1 location
• SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization
  NCT06389097 · Phase: Not specified · Ages: 18 Years to 100 Years · Sex: All (male and female) · 1 location
• Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
  NCT05877430 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Simulation-Free Celiac Plexus Pain Ablation Using Stereotactic Body Radiotherapy in Patients With Cancer-Related Celiac Pain
  NCT07636382 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
  NCT04900818 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 21 locations
• Survival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer
  NCT06338683 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Using Tumor Models to Determine Treatments
  NCT06813079 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Related conditions

Trials recruiting for Advanced Cancer often also study these conditions. Each links to its own recruiting-trial list.

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for Advanced Cancer trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.